

Proposal for the recognition of minimally differentiated

British Journal of Haematology

78, 325-329

DOI: [10.1111/j.1365-2141.1991.tb04444.x](https://doi.org/10.1111/j.1365-2141.1991.tb04444.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Acute myeloid leukemia and related precursor neoplasms. , 2011, , 272-309.		2
2	Proposed Criteria for Classification of Acute Myeloid Leukemia in Dogs and Cats. Veterinary Clinical Pathology, 1991, 20, 63-82.	0.3	124
5	Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis. Leukemia Research, 1992, 16, 51-54.	0.4	30
6	The diagnosis of acute leukemia with undifferentiated or minimally differentiated blasts. Annals of Hematology, 1992, 64, 161-165.	0.8	34
7	Phenotypic and clinical heterogeneity of CD56-positive acute nonlymphoblastic leukemia. Annals of Hematology, 1992, 64, 78-82.	0.8	20
8	The role of an antiâ€”myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry. British Journal of Haematology, 1992, 80, 62-68.	1.2	67
9	DETECTION OF Hâ€”RAS POINT MUTATION IN MYELOPEROXIDASE NEGATIVE ACUTE MYELOGENOUS LEUKAEMIA (FAB: AMLâ€”M0). British Journal of Haematology, 1992, 82, 776-777.	1.2	0
10	The value of detecting surface and cytoplasmic antigens in acute myeloid leukaemia. British Journal of Haematology, 1992, 81, 178-183.	1.2	33
11	Acute myeloid leukaemia with an unusual phenotype: myeloperoxidase (+), CD13 (-), CD14 (-) and CD33 (-). British Journal of Haematology, 1992, 81, 374-377.	1.2	16
12	CLINICOâ€”PATHOLOGICAL FEATURES OF MINIMALLY DIFFERENTIATED ACUTE MYELOID LEUKAEMIA (AMLâ€”M0). British Journal of Haematology, 1992, 81, 458-459.	1.2	9
13	Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3. British Journal of Haematology, 1993, 83, 158-165.	1.2	74
14	Minimally differentiated acute leukemia. Leukemia Research, 1993, 17, 199-208.	0.4	11
15	Flow cytometric detection of cytoplasmic antigens in acute leukemias: Implications for lineage assignment. Leukemia Research, 1993, 17, 455-461.	0.4	18
16	Classification of myeloproliferative disorders in cats using criteria proposed by the animal leukaemia study group: A retrospective study of 181 cases (1969â€”1992). Comparative Haematology International, 1993, 3, 125-134.	0.5	33
17	Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). Annals of Hematology, 1993, 66, 67-70.	0.8	24
18	Acute lymphoblastic leukaemia in adults: Immunological subtypes and clinical features at presentation. Annals of Hematology, 1993, 66, 277-282.	0.8	12
19	Acute Myeloblasts Leukemia with Minimal Myeloid Differentiation (FAB AML-M0): A Study of Eleven Cases. Leukemia and Lymphoma, 1993, 12, 103-108.	0.6	23
20	An Unusual Presentation of Acute Mveloid Leukaemia with Pericardial and Pleural Effusions Due to Granulocytic Sarcoma. Leukemia and Lymphoma, 1993, 11, 305-307.	0.6	32

#	ARTICLE	IF	CITATIONS
21	Clinical Review on Features and Cytogenetic Patterns in Adult Acute Myeloid Leukemia with Lymphoid Markers. <i>Leukemia and Lymphoma</i> , 1993, 9, 285-291.	0.6	11
22	De Novo Acute Leukemia with a Sole 5q-: Morphological, Immunological, and Clinical Correlations. <i>Leukemia and Lymphoma</i> , 1993, 11, 387-392.	0.6	4
23	Acquisition of CD13 and CD33 Expression at Relapse on Acute Myeloid Leukemia Cells with an Unusual Phenotype: MPO+CD13-CD33-.. <i>Internal Medicine</i> , 1993, 32, 733-736.	0.3	3
24	Immunophenotypic Analysis of Acute Leukemia. <i>American Journal of Clinical Pathology</i> , 1993, 99, 504-512.	0.4	40
25	Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma [see comments]. <i>Blood</i> , 1993, 81, 2399-2405.	0.6	127
26	mb-1: a new marker for B-lineage lymphoblastic leukemia. <i>Blood</i> , 1993, 82, 853-857.	0.6	39
27	Alterations in the deleted in colorectal carcinoma gene in human primary leukemia. <i>Blood</i> , 1993, 82, 927-930.	0.6	39
28	Management of Acute Leukemia. <i>Baylor University Medical Center Proceedings</i> , 1993, 6, 38-39.	0.2	0
29	Characterization of Myeloid or Lymphoid Acute Leukemia by a Chemiluminescence Assay. Comparison with Immunocytochemistry Using an Antimyeloperoxidase Antibody. <i>Acta Haematologica</i> , 1993, 90, 19-24.	0.7	7
30	Advances in the Diagnosis of Acute Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 1993, 7, 1-46.	0.9	12
31	The diagnostic and prognostic value of immunophenotyping in acute leukemia. <i>Pathology</i> , 1993, 25, 367-374.	0.3	14
32	Flow Cytometry: Clinical And Research Applications In Hematologic Malignancies. <i>Hematology/Oncology Clinics of North America</i> , 1994, 8, 703-723.	0.9	7
33	Essential Thrombocythemia Terminating in Acute Leukemia with Minimal Myeloid Differentiation -A Brief Review of Recent Literature. <i>Acta Haematologica</i> , 1994, 91, 84-88.	0.7	59
34	Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0). <i>Blood</i> , 1994, 83, 1619-1625.	0.6	75
35	Variable detection of myeloid antigens in childhood acute lymphoblastic leukaemia.. <i>Journal of Clinical Pathology</i> , 1994, 47, 1006-1009.	1.0	15
36	Immunophenotyping in the diagnosis of acute leukaemias. General Haematology Task Force of BCSH.. <i>Journal of Clinical Pathology</i> , 1994, 47, 777-781.	1.0	22
37	Monoclonal Antibody Anti-MPO is Useful in Recognizing Minimally Differentiated Acute Myeloid Leukaemia. <i>Leukemia and Lymphoma</i> , 1994, 12, 233-239.	0.6	21
38	Myeloperoxidase Gene Expression in Normal Granulopoiesis and Acute Leukemias. <i>Leukemia and Lymphoma</i> , 1994, 15, 209-226.	0.6	30

#	ARTICLE	IF	CITATIONS
39	Daunorubicin (DNR) Accumulation in Fresh Leukemic Cells: Correlation with Clinical and Biological Features. <i>Leukemia and Lymphoma</i> , 1994, 13, 291-296.	0.6	2
40	The Value of Scoring Systems for the Diagnosis of Biphenotypic Leukemia and Mature B-Cell Disorders. <i>Leukemia and Lymphoma</i> , 1994, 13, 11-14.	0.6	107
41	Immunophenotypic Features of Childhood and Adult Acute Lymphoblastic Leukemia (ALL): Experience of the German Multicentre Trials ALL-BFM and GMALL. <i>Leukemia and Lymphoma</i> , 1994, 13, 71-76.	0.6	31
42	Trisomy 21 as the sole clonal aberration in a patient with acute myelomonocytic leukemia with abnormal bone marrow eosinophils and extramedullary involvement. <i>Annals of Hematology</i> , 1994, 68, 93-95.	0.8	2
43	Prognostic significance of the blast self-renewal capacity in patients with acute myeloid leukemia. <i>Cancer</i> , 1994, 73, 92-97.	2.0	10
44	A knowledge-based system for the interpretation of flow cytometry data in leukemias and lymphomas. <i>Cytometry</i> , 1994, 17, 266-273.	1.8	22
45	Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. <i>Cytometry</i> , 1994, 18, 187-198.	1.8	129
46	Successful treatment of low dose cytosine arabinoside for acute myelofibrosis with immature myeloblast (AML-MO). <i>American Journal of Hematology</i> , 1994, 46, 154-155.	2.0	2
47	A novel case of acute myeloid leukemia of M0 form with t(10;11)(p13;q21). <i>American Journal of Hematology</i> , 1994, 47, 64-65.	2.0	3
48	Possibilities and limitations of cytochemical methods in diagnosis of acute leukemia. <i>Micron</i> , 1994, 25, 317-329.	1.1	2
49	Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia. <i>Leukemia Research</i> , 1994, 18, 313-318.	0.4	15
50	Near-tetraploid poorly differentiated acute myeloid leukemia M0 diagnosed by short-term cultures with a Phorbol ester TPA. <i>Leukemia Research</i> , 1994, 18, 493-497.	0.4	17
51	2 Immunophenotypic classification of acute lymphoblastic leukaemia. <i>Best Practice and Research: Clinical Haematology</i> , 1994, 7, 235-262.	1.1	55
52	3 Morphology and cytochemistry of acute lymphoblastic leukaemia. <i>Best Practice and Research: Clinical Haematology</i> , 1994, 7, 263-272.	1.1	17
53	Minimally differentiated acute myeloid leukaemia (AML-MO): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. <i>British Journal of Haematology</i> , 1994, 88, 784-793.	1.2	46
54	Blast cells in child and adult AML: comparative study of morphocytochemical, immunological and cytogenetic characteristics. <i>British Journal of Haematology</i> , 1994, 87, 708-714.	1.2	6
55	Unexpected remission of acute myeloid leukaemia after GM-CSF. <i>British Journal of Haematology</i> , 1994, 87, 835-838.	1.2	15
56	Minor myeloid component in Ph chromosome-positive acute lymphoblastic leukaemia: correlation with cytogenetic pattern and implication for poor response to therapy. <i>British Journal of Haematology</i> , 1994, 87, 515-522.	1.2	15

#	ARTICLE	IF	CITATIONS
57	Acute leukemia in adults: recent developments in diagnosis and treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 1994, 44, 326-352.	157.7	39
58	The Use of Monoclonal Antibodies and Immune Markers in the Diagnosis, Prognosis, and Therapy of Acute Leukemia. <i>Transfusion Medicine Reviews</i> , 1994, 8, 59-75.	0.9	6
59	Balanced 7;12 translocation associated with minimally differentiated acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1994, 73, 171-172.	1.0	2
60	IMMUNOPHENOTYPING OF ACUTE LEUKAEMIAS : A CRITICAL ANALYSIS OF 35 CASES. <i>Medical Journal Armed Forces India</i> , 1995, 51, 165-169.	0.3	0
61	CD4 Predicts Nonlymphocytic Lineage in Acute Leukemia: Insights From Analysis of 125 Cases Using Two-Color Flow Cytometry. <i>American Journal of Clinical Pathology</i> , 1995, 104, 204-211.	0.4	19
62	Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. <i>British Journal of Haematology</i> , 1995, 89, 250-257.	1.2	91
63	Low incidence of MDR1 expression in acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 1995, 90, 369-374.	1.2	27
64	A specific chromosome abnormality of t(4;12)(q11-12;p13) in CD7+acute leukaemia. <i>British Journal of Haematology</i> , 1995, 90, 850-854.	1.2	19
65	Minimally differentiated erythroleukaemia (AML M6 Variant'): a rare subset of AML distinct from AML M6. <i>British Journal of Haematology</i> , 1995, 90, 868-875.	1.2	62
66	Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. <i>British Journal of Haematology</i> , 1995, 89, 250-257.	1.2	18
67	Monoclonal antibodies in the management of acute leukemia. <i>American Journal of Hematology</i> , 1995, 50, 188-199.	2.0	12
68	Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia. <i>Annals of Hematology</i> , 1995, 71, 13-27.	0.8	9
69	AML-M0: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. <i>Annals of Hematology</i> , 1995, 70, 297-300.	0.8	17
71	Interleukin-1 β (IL-1 β) and acute leukemia: In vitro proliferative response to IL-1 β , IL-1 β content of leukemic cells and treatment outcome. <i>Leukemia Research</i> , 1995, 19, 35-41.	0.4	11
72	Morphological comparison of dysplastic changes between de novo acute myeloid leukemia (AML) with trilineage myelodysplasia and AML developed from de novo myelodysplastic syndromes. <i>Leukemia Research</i> , 1995, 19, 121-125.	0.4	14
73	Relationship between responsiveness to colony stimulating factors (CSFs) and surface phenotype of leukemic blasts. <i>Leukemia Research</i> , 1995, 19, 195-201.	0.4	10
74	Acute leukemic transformation of myelodysplastic syndrome—Immunophenotypic, genotypic, and cytogenetic studies. <i>Leukemia Research</i> , 1995, 19, 595-603.	0.4	16
75	Combination chemotherapy of carboplatin and cytosine arabinoside for high-risk leukemia: A pilot study. <i>Leukemia Research</i> , 1995, 19, 899-903.	0.4	6

#	ARTICLE	IF	CITATIONS
76	Granulocyte colony-stimulating factor in acute myeloid leukemia. <i>Stem Cells</i> , 1995, 13, 647-654.	1.4	9
77	Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. <i>Blood</i> , 1995, 86, 3097-3108.	0.6	152
78	Cytogenetic profile of minimally differentiated (FAB M0) acute myeloid leukemia: correlation with clinicobiologic findings [see comments]. <i>Blood</i> , 1995, 85, 3688-3694.	0.6	97
79	The biology and treatment of acute lymphoblastic leukemia in adults. <i>Blood</i> , 1995, 85, 1151-1168.	0.6	189
80	A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). <i>Blood</i> , 1995, 86, 457-462.	0.6	432
81	Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. <i>Journal of Clinical Oncology</i> , 1995, 13, 11-18.	0.8	113
82	Contribution of immunophenotype in the diagnosis and classification of haemopoietic malignancies. <i>Journal of Clinical Pathology</i> , 1995, 48, 194-197.	1.0	18
83	Expression of c-kit Receptor (CD 117) and CD34 in Leukemic Cells. <i>Leukemia and Lymphoma</i> , 1995, 16, 297-305.	0.6	26
84	Granulocyte-Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 1995, 332, 1671-1677.	13.9	441
85	Clinical, Morphologic, Cytogenetic and Prognostic Implications of CD34 Expression in Childhood and Adult de novo AML. <i>Leukemia and Lymphoma</i> , 1995, 17, 417-426.	0.6	23
86	Usefulness of Immunocytochemistry for Phenotypical Analysis of Acute Leukemia; Improved Fixation Procedure and Comparative Study with Flow Cytometry. <i>Leukemia and Lymphoma</i> , 1995, 16, 319-327.	0.6	4
87	Immunological Definition of Acute Minimally Differentiated Myeloid Leukemia (MO) and Acute Undifferentiated Leukemia (AUL). <i>Leukemia and Lymphoma</i> , 1995, 18, 13-17.	0.6	17
88	CD7 Expression in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1995, 17, 111-119.	0.6	43
89	Routine and specialised techniques in the diagnosis of haematological neoplasms. <i>Journal of Clinical Pathology</i> , 1995, 48, 501-508.	1.0	6
90	Childhood Leukemias. <i>New England Journal of Medicine</i> , 1995, 332, 1618-1630.	13.9	440
91	Use of myeloperoxidase mRNA in monitoring patients with acute myelogenous leukemia for early detection of circulating blasts. <i>Molecular Diagnosis and Therapy</i> , 1996, 1, 313-319.	1.3	0
92	The FAB classification for acute myeloid leukaemia: is it outdated?. <i>Netherlands Journal of Medicine</i> , 1996, 49, 126-131.	0.6	5
93	Differences in the chromosomal profile of AML-M0 versus AML-M1: response [letter; comment] [see comments]. <i>Blood</i> , 1996, 87, 5381-5382.	0.6	2

#	ARTICLE	IF	CITATIONS
94	Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. <i>Blood</i> , 1996, 87, 1484-1494.	0.6	47
95	Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. <i>Blood</i> , 1996, 87, 1997-2004.	0.6	111
96	Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. <i>Catalan Group for Bone Marrow Transplantation.. Journal of Clinical Oncology</i> , 1996, 14, 1353-1363.	0.8	31
97	Lymphoid-Associated Antigen Expression by Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 1996, 106, 185-191.	0.4	30
98	Detection and Classification of Acute Leukemia by the Coulter STKS Hematology Analyzer. <i>American Journal of Clinical Pathology</i> , 1996, 106, 352-358.	0.4	12
99	Paraffin Section Immunophenotyping of Acute Leukemias in Bone Marrow Specimens. <i>American Journal of Clinical Pathology</i> , 1996, 106, 462-468.	0.4	58
100	Myeloid Antigen, CD13, CD14, and/or CD33 Expression Is Restricted to Certain Lymphoid Neoplasms. <i>American Journal of Clinical Pathology</i> , 1996, 105, 761-768.	0.4	31
101	Clinical significance of LEA-1 expression in adult acute myeloid leukemia. <i>Leukemia Research</i> , 1996, 20, 327-332.	0.4	10
102	Diagnostic criteria for hypocellular acute leukemia: A clinical entity distinct from overt acute leukemia and myelodysplastic syndrome. <i>Leukemia Research</i> , 1996, 20, 563-574.	0.4	31
103	Usefulness and limitations of serum and urine lysozyme levels in the classification of acute myeloid leukemia: An analysis of 208 cases. <i>Leukemia Research</i> , 1996, 20, 467-472.	0.4	21
104	Timed sequential chemotherapy for advanced acute myeloid leukemia. <i>Hematology and Cell Therapy</i> , 1996, 38, 161-167.	0.7	17
105	Immunophenotypic characterization of acute leukemias and chronic lymphoproliferative disorders: practical recommendations and classifications. <i>Hematology and Cell Therapy</i> , 1996, 38, 471-486.	0.7	33
106	Neural network analysis of flow cytometry immunophenotype data. <i>IEEE Transactions on Biomedical Engineering</i> , 1996, 43, 803-810.	2.5	27
107	Cytogenetic and clinicobiological features of acute leukemia with stem cell phenotype: Study of nine cases. <i>Cancer Genetics and Cytogenetics</i> , 1996, 92, 31-36.	1.0	28
108	Development of minimally differentiated acute myeloblastic leukemia with novel isochromosome 18p and antecedent aplastic anemia. <i>Cancer Genetics and Cytogenetics</i> , 1996, 92, 1-3.	1.0	0
109	2 Special cytological subtypes of acute myeloid leukaemias and myelodysplastic syndromes. <i>Best Practice and Research: Clinical Haematology</i> , 1996, 9, 19-33.	1.1	8
110	3 Immunophenotyping of AML and MDS and detection of residual disease. <i>Best Practice and Research: Clinical Haematology</i> , 1996, 9, 35-55.	1.1	11
111	Identification of drug-resistant myeloid leukemic cells by measurement of DNA content, nuclear area, and detection of P-glycoprotein. , 1996, 77, 878-887.		5

#	ARTICLE	IF	CITATIONS
112	Intensive treatment of patients age 60 years and older with De novo acute myeloid leukemia: Analysis of prognostic factors. , 1996, 77, 2476-2488.		38
113	Diagnosis and treatment of acute myelogenous leukemia in childhood. Critical Reviews in Oncology/Hematology, 1996, 22, 183-196.	2.0	2
114	Minimally differentiated acute myeloid leukaemia revealed by specific cutaneous lesions. British Journal of Dermatology, 1996, 135, 119-123.	1.4	3
115	Establishment of an Undifferentiated Leukemia Cell Line (Kasumi-3) with t(3;7)(q27;q22) and Activation of the EVI1 Gene. Japanese Journal of Cancer Research, 1996, 87, 269-274.	1.7	34
116	Hematopoietic and Lymphatic Malignancies in Vehicle Mechanics. Critical Reviews in Toxicology, 1997, 27, 443-494.	1.9	20
117	Molecular Analysis of Minimally Differentiated Acute Myeloid Leukemia with Chromosome 16 Inversion. Leukemia and Lymphoma, 1997, 24, 319-325.	0.6	0
118	P-Glycoprotein Expression in De Novo Acute Myeloid Leukemia. Leukemia and Lymphoma, 1997, 27, 257-274.	0.6	29
119	Serum Interleukin-6 Levels in Adult Acute Myelogenous Leukemia: Relationship with Disease Characteristics and Outcome. Leukemia and Lymphoma, 1997, 24, 291-300.	0.6	11
120	Presence of t(8;21)(q22;q22) in Myeloperoxidase-Positive, Myeloid Surface Antigenâ€“Negative Acute Myeloid Leukemia. American Journal of Clinical Pathology, 1997, 107, 68-73.	0.4	29
121	Useful Panel of Antibodies for the Classification of Acute Leukemia by Immunohistochemical Methods in Bone Marrow Trepchine Biopsy Specimens. American Journal of Clinical Pathology, 1997, 107, 410-418.	0.4	51
122	Characterization of Acute Leukemia with t(4;12). Leukemia and Lymphoma, 1997, 25, 47-53.	0.6	23
123	Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy.. Journal of Clinical Oncology, 1997, 15, 2262-2268.	0.8	39
124	Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.. Journal of Clinical Oncology, 1997, 15, 3496-3506.	0.8	122
125	Induction Failure in <i>de novo</i> Acute Myelogenous Leukemia is Associated with Expression of High Levels o CD34 Antigen by the Leukemic Blasts. Leukemia and Lymphoma, 1997, 26, 299-306.	0.6	9
126	Expression of Sialosyl-T and Disialosyl-T Antigens in Erythroid Cells. Leukemia and Lymphoma, 1997, 25, 403-414.	0.6	10
127	Combined method for simultaneous morphology, immunophenotype and karyotype (MAC) in leukemias. Sao Paulo Medical Journal, 1997, 115, 1336-1342.	0.4	2
128	Biological Pattern of AML-M0 Versus AML-M1: Response. Blood, 1997, 89, 345-345.	0.6	9
129	Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Comparison of 25 Cases With Other French-American-British Subtypes. Blood, 1997, 89, 621-629.	0.6	75

#	ARTICLE	IF	CITATIONS
130	CD7+ and CD56+ Myeloid/Natural Killer Cell Precursor Acute Leukemia: A Distinct Hematolymphoid Disease Entity. <i>Blood</i> , 1997, 90, 2417-2428.	0.6	183
131	Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy. <i>Blood</i> , 1997, 90, 2863-2892.	0.6	390
132	Chemotherapy of Acute Myelocytic Leukemia in Children. <i>Annals of the New York Academy of Sciences</i> , 1997, 824, 84-90.	1.8	0
133	Proliferative effects of several hematopoietic growth factors on acute myelogenous leukemia cells and correlation with treatment outcome. <i>Leukemia</i> , 1997, 11, 2125-2130.	3.3	19
134	A translocation between 3q21 and 12q24 in a patient with minimally differentiated acute myeloid leukemia (AML-MO). <i>Cancer Genetics and Cytogenetics</i> , 1997, 97, 90-93.	1.0	11
135	Absence of mutations in the RET gene in acute myeloid leukemia. <i>Annals of Hematology</i> , 1997, 75, 87-90.	0.8	13
136	Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. <i>Hematology and Cell Therapy</i> , 1997, 39, 11-18.	0.7	51
137	Adult acute leukemia. <i>Current Problems in Cancer</i> , 1997, 21, 1-64.	1.0	24
138	U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Medical indications. <i>Cytometry</i> , 1997, 30, 249-263.	1.8	63
139	Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. <i>Leukemia</i> , 1998, 12, 1056-1063.	3.3	87
140	Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics. <i>Leukemia</i> , 1998, 12, 1071-1075.	3.3	25
141	Differences in CD14 and Î±-naphthyl acetate esterase positivity and relation to prognosis in AML. <i>Leukemia Research</i> , 1998, 22, 25-30.	0.4	6
142	Three cases of near-tetraploid acute myeloid leukemias originating in pluripotent myeloid progenitors. <i>Leukemia Research</i> , 1998, 22, 581-588.	0.4	29
143	Clinical significance of granulocyte colony-stimulating factor (G-CSF) receptor expression in acute myeloid leukemia. <i>Leukemia Research</i> , 1998, 22, 31-37.	0.4	4
144	Expression profiles of I and sialosyl-I antigens on blood cells: the sialosyl-I antigen is expressed along the monocytic differentiation. <i>Leukemia Research</i> , 1998, 22, 1029-1036.	0.4	4
145	Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. <i>European Journal of Immunology</i> , 1998, 28, 90-103.	1.6	78
146	Biologic and clinical significance of CD7 expression in acute myeloid leukemia. , 1998, 58, 278-284.		48
147	An autopsy case of granulocytic sarcoma of the porta hepatis causing obstructive jaundice. <i>Journal of Gastroenterology</i> , 1998, 33, 428.	2.3	29

#	ARTICLE	IF	CITATIONS
148	Differential expression of the RET gene in human acute myeloid leukemia. <i>Annals of Hematology</i> , 1998, 77, 207-210.	0.8	12
149	Repeated Cycles of G-CSF-Combined Postremission Chemotherapy for Acute Myeloid Leukemia in a First Complete Remission: A Pilot Study. <i>Stem Cells</i> , 1998, 16, 280-287.	1.4	2
150	Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein overexpression. <i>British Journal of Haematology</i> , 1998, 100, 147-155.	1.2	129
151	Trisomy 13 and myeloid malignancy " characteristic blast cell morphology: a United Kingdom Cancer Cytogenetics Group survey. <i>British Journal of Haematology</i> , 1998, 101, 749-752.	1.2	38
152	Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. <i>British Journal of Haematology</i> , 1998, 103, 740-749.	1.2	73
153	Systematic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. <i>British Journal of Haematology</i> , 1998, 102, 740-749.	1.2	33
154	Acute myeloid leukaemias. <i>European Journal of Cancer</i> , 1998, 34, 862-872.	1.3	18
155	Comparison of Referring and Tertiary Cancer Center Physicians' Diagnoses in Patients with Leukemia. <i>American Journal of Medicine</i> , 1998, 104, 246-251.	0.6	10
156	Dyshematopoiesis in De Novo Acute Myeloid Leukemia: Cell Biological Features and Prognostic Significance. <i>Leukemia and Lymphoma</i> , 1998, 29, 523-531.	0.6	9
157	Classification of acute leukaemia: the need to incorporate cytogenetic and molecular genetic information. <i>Journal of Clinical Pathology</i> , 1998, 51, 420-423.	1.0	15
158	The Immunophenotype of Adult Acute Myeloid Leukemia: High Frequency of Lymphoid Antigen Expression and Comparison of Immunophenotype, French-American-British Classification, and Karyotypic Abnormalities. <i>American Journal of Clinical Pathology</i> , 1998, 109, 211-220.	0.4	129
159	Acute Myeloid Leukemia With Minimal Differentiation: A Multiple Parameter Study. <i>American Journal of Clinical Pathology</i> , 1998, 109, 32-38.	0.4	44
160	Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. <i>European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.</i> <i>Journal of Clinical Oncology</i> , 1998, 16, 872-881.	0.8	262
161	Homozygous Deletion of the p16INK4A Gene Occurs More Frequently in CD2+ Than in CD2- T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 1998, 91, 1829-1830.	0.6	3
162	Relevance of <i>in Vitro</i> Leukaemia Cell Survival to Short- and Long Term Clinical Outcome in AML. <i>Leukemia and Lymphoma</i> , 1999, 32, 327-337.	0.6	7
163	Diagnosis of Childhood Acute Myeloid Leukemia. <i>Clinics in Laboratory Medicine</i> , 1999, 19, 187-238.	0.7	12
164	Biallelic and Heterozygous Point Mutations in the Runt Domain of the AML1/PEBP2 Gene Associated With Myeloblastic Leukemias. <i>Blood</i> , 1999, 93, 1817-1824.	0.6	377
165	Isolated Tetrasomy 8 in Minimally Differentiated Acute Myeloid Leukemia (AML-M0). <i>Leukemia and Lymphoma</i> , 1999, 33, 581-585.	0.6	13

#	ARTICLE	IF	CITATIONS
166	The Impact of Karyotype on Remission Rates in Adult Patients with de novo Acute Myeloid Leukemia Receiving High-Dose Cytarabine-Based Induction Chemotherapy. <i>Leukemia and Lymphoma</i> , 1999, 34, 553-560.	0.6	10
167	Acute Minimally Differentiated Myeloid Leukemia (M0) with Inv(3)(q21q26). <i>Leukemia and Lymphoma</i> , 1999, 35, 627-630.	0.6	7
168	Leukemia Arising out of Paroxysmal Nocturnal Hemoglobinuria. <i>Leukemia and Lymphoma</i> , 1999, 32, 401-426.	0.6	57
169	Expression of the C-Kit Receptor (CD117) is a Feature of Almost All Subtypes of De Novo Acute Myeloblastic Leukemia (AML), Including Cytogenetically Good-Risk AML, and Lacks Prognostic Significance. <i>Leukemia and Lymphoma</i> , 1999, 34, 85-94.	0.6	55
170	Cancer Surveillance Series: Recent Trends in Childhood Cancer Incidence and Mortality in the United States. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1051-1058.	3.0	362
171	Definition of a standard-risk group in children with AML. <i>British Journal of Haematology</i> , 1999, 104, 630-639.	1.2	122
172	Plasminogen activation in human acute leukaemias. <i>British Journal of Haematology</i> , 1999, 105, 920-927.	1.2	22
173	CASE REPORT. <i>International Journal of Laboratory Hematology</i> , 1999, 21, 293-295.	0.2	8
174	Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. <i>British Journal of Haematology</i> , 1999, 105, 155-162.	1.2	170
175	The RET receptor tyrosine kinase, but not its specific ligand, GDNF, is preferentially expressed by acute leukaemias of monocytic phenotype and is up-regulated upon differentiation. <i>British Journal of Haematology</i> , 1999, 105, 225-240.	1.2	19
176	Acute leukaemia immunophenotyping in bone-marrow routine sections. <i>British Journal of Haematology</i> , 1999, 105, 394-401.	1.2	51
177	A more precise diagnosis of AML M0, a part of which exhibits a near-tetraploid karyotype. <i>Leukemia</i> , 1999, 13, 145-146.	3.3	2
178	Granulocyte macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). <i>Leukemia</i> , 1999, 13, 1214-1220.	3.3	75
179	Selective usage of D-type cyclins in lymphoid malignancies. <i>Leukemia</i> , 1999, 13, 1335-1342.	3.3	47
180	The immunophenotype of minimally differentiated acute myeloid leukemia (AML-M0): reduced immunogenicity and high frequency of CD34+/CD38+ leukemic progenitors. <i>Leukemia</i> , 1999, 13, 1513-1518.	3.3	41
181	Minimally differentiated acute myeloid leukemia in Taiwan: predominantly occurs in children less than 3 years and adults between 51 and 70 years. <i>Leukemia</i> , 1999, 13, 1506-1512.	3.3	15
182	Specific skin manifestations in CD56 positive acute myeloid leukemia. <i>Journal of Cutaneous Pathology</i> , 1999, 26, 1-5.	0.7	36
183	Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 1999, 341, 1051-1062.	13.9	1,291

#	ARTICLE	IF	CITATIONS
184	Adult Precursor-B Acute Lymphoblastic Leukemia with Translocations Involving Chromosome Band 19p13 is Associated with Poor Prognosis. <i>Cancer Genetics and Cytogenetics</i> , 1999, 109, 58-65.	1.0	30
185	Acute Myeloblastic Leukemia (M0) with an Unusual Chromosomal Abnormality. <i>Cancer Genetics and Cytogenetics</i> , 1999, 111, 175-177.	1.0	4
186	P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. <i>Leukemia Research</i> , 1999, 23, 451-465.	0.4	33
187	Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. <i>Leukemia Research</i> , 1999, 23, 615-624.	0.4	135
188	Mixed-lineage leukemia with t(10;11)(p13;q21): An analysis ofAF10-CALM andCALM-AF10 fusion mRNAs and clinical features. , 1999, 25, 33-39.		46
189	Altered expression of CD45 isoforms in differentiation of acute myeloid leukemia. , 1999, 62, 159-164.		10
190	Comprehensive review of adult acute myelogenous leukemia: Cytomorphological, enzyme cytochemical, flow cytometric immunophenotypic, and cytogenetic findings. , 1999, 13, 19-26.		22
191	Uncommon patterns of presentation of leukemia. , 1999, 17, 11-29.		10
192	Immunocytochemical analysis of MNDA in tissue sections and sorted normal bone marrow cells documents expression only in maturing normal and neoplastic myelomonocytic cells and a subset of normal and neoplastic B lymphocytes. <i>Human Pathology</i> , 1999, 30, 1040-1049.	1.1	45
193	AML-M0: A Review of Laboratory Features and Proposal of New Diagnostic Criteria. <i>Blood Cells, Molecules, and Diseases</i> , 1999, 25, 120-129.	0.6	14
194	Pseudoaneurysm of the Subclavian Artery due to Xanthomonas Pneumonia in a Patient with Acute Myeloid Leukemia. Its Rupture Treated by Transcatheter Coil Embolization.. <i>Internal Medicine</i> , 1999, 38, 671-674.	0.3	10
195	Childhood cancer in new zealand 1990 to 1993. <i>Pathology</i> , 1999, 31, 83-89.	0.3	10
196	Acute Lymphoblastic Leukemia: Survey of Immunophenotype, French-American-British Classification, Frequency of Myeloid Antigen Expression, and Karyotypic Abnormalities in 210 Pediatric and Adult Cases. <i>American Journal of Clinical Pathology</i> , 1999, 111, 467-476.	0.4	100
197	The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders. <i>Pathology</i> , 1999, 31, 382-392.	0.3	26
198	Cytogenetically cryptic AML1-ETO and CBFbeta-MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2000, 111, 1051-1056.	1.2	60
199	Minimally Differentiated Erythroleukemia: Recognition of Erythroid Precursors and Progenitors. <i>Internal Medicine</i> , 2000, 39, 761-762.	0.3	6
200	Characterization of CD13 and CD33 Surface Antigen in CD33-Negative Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2000, 114, 29-34.	0.4	11
201	Minimally differentiated acute myeloid leukemia (AML-M0) in children: A single center experience. , 2000, 34, 364-365.		3

#	ARTICLE	IF	CITATIONS
202	Modified intranuclear organization of regulatory factors in human acute leukemias: Reversal after treatment. , 2000, 77, 30-43.		10
203	Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. Bone Marrow Transplantation, 2000, 25, 1203-1208.	1.3	18
204	Acute myeloid leukaemia triggering via CD40 induces leukocyte chemoattraction and cytotoxicity against allogenic or autologous leukemic targets. Leukemia, 2000, 14, 123-128.	3.3	13
205	Survival time in a population-based consecutive series of adult acute myeloid leukemia â€“ the prognostic impact of karyotype during the time period 1976â€“1993. Leukemia, 2000, 14, 1039-1043.	3.3	15
206	Limitations of the diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-MO). Leukemia, 2000, 14, 2013-2014.	3.3	5
207	Expression and prognostic significance of survivin in <i>de novo</i> acute myeloid leukaemia. British Journal of Haematology, 2000, 111, 196-203.	1.2	86
208	Cytogenetically cryptic AML1â€“ETO and CBF12â€“MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia. British Journal of Haematology, 2000, 111, 1051-1056.	1.2	9
209	Minimally differentiated acute myeloid leukemia (AML-MO) with extensive erythrophagocytosis and del(20)(q11) chromosome abnormality. Leukemia Research, 2000, 24, 87-90.	0.4	15
210	Erythroblastic and/or megakaryocytic dysplasia in de novo acute myeloid leukemias MOâ€“M5 show relation to myelodysplastic syndromes and delimit two main categories. Leukemia Research, 2000, 24, 207-215.	0.4	11
211	Deletion of Xq23 is a recurrent karyotypic abnormality in acute myeloid leukemia. Cancer Genetics and Cytogenetics, 2000, 122, 33-36.	1.0	9
212	A Novel t(11;12)(q23â€“24;q24) in a Case of Minimally-Differentiated Acute Myeloid Leukemia (AML-MO). Cancer Genetics and Cytogenetics, 2000, 118, 76-79.	1.0	3
213	Immunophenotyping of leukemia. Journal of Immunological Methods, 2000, 243, 59-75.	0.6	128
214	Near-tetraploid minimally differentiated acute myeloid leukemia with extensive erythrophagocytosis by leukemic blasts. Annals of Hematology, 2000, 79, 36-39.	0.8	16
215	The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood, 2000, 96, 870-877.	0.6	124
216	Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood, 2000, 96, 3154-3160.	0.6	152
217	High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP21±B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood, 2000, 96, 2862-2869.	0.6	241
218	Multifaceted Approach to the Diagnosis and Classification of Acute Leukemias. Clinical Chemistry, 2000, 46, 1252-1259.	1.5	38
219	Morphology and Classification of Acute Myeloid Leukemias. Clinics in Laboratory Medicine, 2000, 20, 1-16.	0.7	10

#	ARTICLE	IF	CITATIONS
220	Flow Cytometric Immunophenotypic Characterization of Pediatric and Adult Minimally Differentiated Acute Myeloid Leukemia (AML-M0). American Journal of Clinical Pathology, 2000, 113, 193-200.	0.4	40
221	Rapid Diagnosis of Acute Promyelocytic Leukemia by Analyzing the Immunocytochemical Pattern of the PML Protein With the Monoclonal Antibody PG-M3. American Journal of Clinical Pathology, 2000, 114, 786-792.	0.4	25
222	Immunohistochemistry Can Be Used to Subtype Acute Myeloid Leukemia in Routinely Processed Bone Marrow Biopsy Specimens. American Journal of Clinical Pathology, 2000, 113, 814-822.	0.4	43
223	Clinical and Biologic Diversity of Leukemias Occurring in Patients with Mastocytosis. Leukemia and Lymphoma, 2000, 37, 473-486.	0.6	101
224	Anti-CD10 immunoperoxidase staining of paraffin-embedded acute leukemias: Comparison with flow cytometric immunophenotyping. Human Pathology, 2000, 31, 1051-1054.	1.1	13
225	IMMUNOPHENOTYPES IN ADULT ACUTE LYMPHOCYTIC LEUKEMIA. Hematology/Oncology Clinics of North America, 2000, 14, 1251-1265.	0.9	23
226	Allogeneic bone marrow transplantation for young adult patients with newly diagnosed acute myeloid leukemia: HLA-Matched sibling donor availability does not improve treatment outcome. Hematology and Cell Therapy, 2000, 42, 119-129.	0.7	3
227	Acute Myeloid Leukemia in the Elderly: Results of an Individualized Approach in Two Centres. Leukemia and Lymphoma, 2000, 39, 521-530.	0.6	7
228	Minimally Differentiated Acute Myeloid Leukemia (AML M0): Clinico-Biological Findings of 29 Cases. Leukemia and Lymphoma, 2000, 37, 105-113.	0.6	24
229	PATHOLOGIC DIAGNOSIS OF ACUTE LYMPHOCYTIC LEUKEMIA. Hematology/Oncology Clinics of North America, 2000, 14, 1209-1235.	0.9	15
230	Laboratory diagnosis of acute myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2001, 14, 1-17.	0.7	6
231	Prognostic factors in acute myeloid leukaemia. Best Practice and Research in Clinical Haematology, 2001, 14, 65-75.	0.7	48
232	Leucemias agudas mieloblásticas. Clasificación. Etiopatogenia. Características citológicas, inmunofenotípicas y moleculares. Medicine, 2001, 8, 2881-2889.	0.0	0
233	Outpatient Supportive Care Following Chemotherapy for Acute Myeloblastic Leukemia. Leukemia and Lymphoma, 2001, 42, 339-346.	0.6	37
234	Acute Myeloid Leukemia in the Setting of Low Dose Weekly Methotrexate Therapy for Rheumatoid Arthritis. Leukemia and Lymphoma, 2001, 42, 371-378.	0.6	12
235	Immunophenotypic analysis of leukocytes in disease. , 2001, , 138-164.		0
236	Osteoblast Biology. , 2001, , 21-71.		15
237	Improved Treatment Results in High-Risk Pediatric Acute Myeloid Leukemia Patients After Intensification With High-Dose Cytarabine and Mitoxantrone: Results of Study Acute Myeloid Leukemia—Berlin-Frankfurt-Münster 93. Journal of Clinical Oncology, 2001, 19, 2705-2713.	0.8	183

#	ARTICLE	IF	CITATIONS
238	Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. <i>Blood</i> , 2001, 98, 2200-2209.	0.6	130
239	High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). <i>Blood</i> , 2001, 97, 3574-3580.	0.6	188
240	Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. <i>Blood</i> , 2001, 98, 548-553.	0.6	197
241	Acute Myelogenous Leukaemia in Patients 60 Years and Older: A Retrospective Analysis from St Bartholomew's Hospital 1969-1999. <i>Hematology</i> , 2001, 6, 163-175.	0.7	2
242	Electron microscopic and cytochemical studies of peroxidase-negative acute nonlymphoblastic leukemia. <i>Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan</i> , 2001, 34, 61-70.	1.8	5
243	Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. <i>British Journal of Haematology</i> , 2001, 113, 153-160.	1.2	20
244	Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. <i>British Journal of Haematology</i> , 2001, 113, 737-745.	1.2	74
245	Truncated STAT proteins are prevalent at relapse of acute myeloid leukemia. <i>Leukemia Research</i> , 2001, 25, 473-482.	0.4	41
246	A novel translocation t(2;9)(q14;p12) in AML-M2 with an uncommon phenotype: myeloperoxidase-positive and myeloid antigen-negative. <i>Leukemia Research</i> , 2001, 25, 501-507.	0.4	3
247	Flow cytometric analysis of cell-surface and intracellular antigens in the diagnosis of acute leukemia. <i>American Journal of Hematology</i> , 2001, 68, 69-74.	2.0	77
248	Morphological diagnoses of the Japan Adult Leukemia Study Group acute myeloid leukemia protocols: Central review. <i>International Journal of Hematology</i> , 2001, 73, 93-99.	0.7	21
249	HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. <i>Leukemia</i> , 2001, 15, 128-133.	3.3	57
250	Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. <i>Leukemia</i> , 2001, 15, 348-354.	3.3	134
251	Clinicopathologic characteristics of leukemia in Japanese children and young adults. <i>Leukemia</i> , 2001, 15, 1256-1261.	3.3	34
252	Minimally differentiated acute myeloid leukemia (AML-M0) with lymphoid presentation at relapse: a case report. <i>Leukemia</i> , 2001, 15, 1673-1674.	3.3	1
253	Detection of myeloperoxidase gene expression by in situ hybridization in a case of granulocytic sarcoma associated with AML-M0. <i>Leukemia</i> , 2001, 15, 1797-1799.	3.3	1
254	Mutations of the Smad4 gene in acute myelogenous leukemia and their functional implications in leukemogenesis. <i>Oncogene</i> , 2001, 20, 88-96.	2.6	83
255	The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology. <i>Cancer Genetics and Cytogenetics</i> , 2001, 130, 160-165.	1.0	59

#	ARTICLE	IF	CITATIONS
256	Clinicopathological features of myeloid/natural killer (NK) cell precursor acute leukemia. <i>Leukemia Research</i> , 2001, 25, 109-113.	0.4	27
257	Recent improvements in outcome for elderly patients with de novo acute myeloblastic leukemia. <i>Leukemia Research</i> , 2001, 25, 685-692.	0.4	12
258	Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001, 25, 603-625.	0.4	1,020
259	Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. <i>Leukemia Research</i> , 2001, 25, 595-602.	0.4	67
260	Smoking and acute myeloid leukemia: associations with morphology and karyotypic patterns and evaluation of dose-response relations. <i>Leukemia Research</i> , 2001, 25, 865-872.	0.4	38
261	Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2001, 66, 160-167.	1.1	13
262	FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia. <i>European Journal of Haematology</i> , 2001, 67, 221-229.	1.1	10
264	Diagnostic Criteria for Minimally Differentiated Acute Myeloid Leukemia (AML-M0). <i>American Journal of Clinical Pathology</i> , 2001, 115, 876-884.	0.4	28
265	Myeloperoxidase Immunoreactivity in Adult Acute Lymphoblastic Leukemia. <i>American Journal of Clinical Pathology</i> , 2001, 116, 25-33.	0.4	40
266	Realistic Pathologic Classification of Acute Myeloid Leukemias. <i>American Journal of Clinical Pathology</i> , 2001, 115, 552-560.	0.4	34
269	Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). <i>Blood</i> , 2002, 100, 4325-4336.	0.6	1,444
270	The Immunophenotype of 325 Adult Acute Leukemias. <i>American Journal of Clinical Pathology</i> , 2002, 117, 380-389.	0.4	74
271	Molecular cytogenetic analysis of 10;11 rearrangements in acute myeloid leukemia. <i>Leukemia</i> , 2002, 16, 344-351.	3.3	50
272	Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23. <i>Leukemia</i> , 2002, 16, 196-202.	3.3	92
273	Die neue WHO-Klassifikation zur Einteilung der akuten myeloischen Leukamien (AML): Vorteile und Probleme im Vergleich zur FAB (French-American-British)-Klassifikation/The New WHO Classification for Acute Myeloid Leukemias: Comparison to the FAB Classification. <i>Laboratoriums Medizin</i> , 2002, 26, 19-22.	0.1	0
275	Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. <i>Blood</i> , 2002, 99, 252-257.	0.6	158
276	Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. <i>Blood</i> , 2002, 100, 2387-2392.	0.6	268
277	1,25-(OH) ₂ -Vitamin D ₃ Suppresses the Bone-Related Runx2/Cbfa1 Gene Promoter. <i>Experimental Cell Research</i> , 2002, 274, 323-333.	1.2	154

#	ARTICLE	IF	CITATIONS
278	Tryptase a Novel Biochemical Marker of Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 2257-2261.	0.6	42
280	Acute leukemia. <i>Clinics in Laboratory Medicine</i> , 2002, 22, 153-192.	0.7	8
281	Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. <i>Blood</i> , 2002, 100, 1224-1232.	0.6	335
282	Aplastic anemia evolving into overt myelodysplastic syndrome/acute myeloid leukemia with t(3;5)(p25;q31). <i>Cancer Genetics and Cytogenetics</i> , 2002, 137, 91-94.	1.0	5
283	Die neue WHO-Klassifikation zur Einteilung der akuten myeloischen Leukamien (AML): Vorteile und Probleme im Vergleich zur FAB (French-American-British)-Klassifikation. The New WHO Classification for Acute Myeloid Leukemias: Comparison to the FAB Classification. <i>Laboratoriums Medizin</i> , 2002, 26, 19-22.	0.1	0
284	Difference in CD22 molecules in human B cells and basophils. <i>Experimental Hematology</i> , 2002, 30, 205-211.	0.2	47
285	Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. <i>Cancer</i> , 2002, 94, 3292-3298.	2.0	72
286	Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 24-32.	1.5	53
287	Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndrome: Identification of new amplification regions by fluorescence in situ hybridization and spectral karyotyping. <i>Genes Chromosomes and Cancer</i> , 2002, 34, 42-47.	1.5	59
288	Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: An underemphasized clinical problem. <i>Annals of Surgical Oncology</i> , 2002, 9, 738-744.	0.7	16
289	Two Independent Clones in Myelodysplastic Syndrome Following Treatment of Acute Myeloid Leukemia. <i>International Journal of Hematology</i> , 2002, 75, 182-186.	0.7	9
290	Intensified Daunorubicin in Induction Therapy and Autologous Peripheral Blood Stem Cell Transplantation in Postremission Therapy (Double-7 Protocol) for Adult Acute Myeloid Leukemia. <i>International Journal of Hematology</i> , 2002, 76, 436-445.	0.7	7
292	Magnetic resonance imaging of femoral marrow predicts outcome in adult patients with acute myeloid leukaemia in complete remission. <i>British Journal of Haematology</i> , 2002, 117, 70-75.	1.2	11
293	Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB) Tj ETQq1 1 0.784314 rgBT /Overl 1.2 48	1.2	48
294	Acute T-lymphoblastic leukemia relapsed with the character of myeloid/natural killer cell precursor phenotype: a case report. <i>Leukemia Research</i> , 2002, 26, 215-219.	0.4	7
295	Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. <i>Leukemia</i> , 2002, 16, 1259-1266.	3.3	171
296	Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy. <i>Leukemia</i> , 2002, 16, 2084-2091.	3.3	67
297	Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro. <i>Leukemia</i> , 2002, 16, 2285-2291.	3.3	20

#	ARTICLE	IF	CITATIONS
298	Prognostic Significance of CD7+CD56+ Phenotype and Chromosome 5 Abnormalities for Acute Myeloid Leukemia M0. <i>International Journal of Hematology</i> , 2003, 77, 482-489.	0.7	31
299	Treatment concepts for elderly patients with acute myeloid leukemia. <i>Wiener Klinische Wochenschrift</i> , 2003, 115, 505-514.	1.0	5
300	Fortschritte in der Klassifikation der akuten lymphatischen Leukamien: Von FAB über MIC und REAL zu WHO. Progress in the Classification of Acute Lymphatic Leukemias: From FAB via MIC and REAL to WHO. <i>Laboratoriums Medizin</i> , 2003, 27, 249-256.	0.1	1
301	AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies. <i>Genes Chromosomes and Cancer</i> , 2003, 38, 1-7.	1.5	45
302	Acute myeloid leukemia in the older patient. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, S17-S26.	2.0	24
303	Megakaryoblastic leukemia cell line MOLM-16 derived from minimally differentiated acute leukemia with myeloid/NK precursor phenotype. <i>Leukemia Research</i> , 2003, 27, 165-171.	0.4	11
304	The role of a Runt domain transcription factor AML1/RUNX1 in leukemogenesis and its clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 45, 129-150.	2.0	68
305	Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study. <i>British Journal of Haematology</i> , 2003, 120, 56-62.	1.2	36
306	Cytogenetic findings in adult de novo acute myeloid leukaemia. A population-based study of 303/337 patients. <i>British Journal of Haematology</i> , 2003, 123, 219-234.	1.2	33
307	HLA-DR antigen-negative acute myeloid leukemia. <i>Leukemia</i> , 2003, 17, 707-715.	3.3	56
308	Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. <i>Leukemia</i> , 2003, 17, 731-737.	3.3	58
309	FLT3-TKD mutation in childhood acute myeloid leukemia. <i>Leukemia</i> , 2003, 17, 883-886.	3.3	69
310	Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials. <i>Leukemia</i> , 2003, 17, 1544-1550.	3.3	19
311	The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype. <i>Leukemia</i> , 2003, 17, 1538-1543.	3.3	49
312	Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype. <i>Leukemia</i> , 2003, 17, 2492-2499.	3.3	59
313	Identification of RUNX1/AML1 as a classical tumor suppressor gene. <i>Oncogene</i> , 2003, 22, 538-547.	2.6	64
314	Classification systems for acute and chronic leukaemias. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 561-582.	0.7	42
315	The prognostic significance of antigen expression in leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 613-628.	0.7	28

#	ARTICLE	IF	CITATIONS
316	Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 4642-4649.	0.8	2,425
317	Acute Myelogenous Leukemia with t(8;21) Identification of a Specific Immunophenotype. <i>Leukemia and Lymphoma</i> , 2003, 44, 1713-1718.	0.6	46
318	Immunohistochemical Detection of VEGF in the Bone Marrow of Patients With Acute Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2003, 119, 663-671.	0.4	35
319	Fortschritte in der Klassifikation der akuten lymphatischen Leukämien: Von FAB über MIC und REAL zu WHO/Progress in the Classification of Acute Lymphatic Leukemias: From FAB via MIC and REAL to WHO. <i>Laboratoriums Medizin</i> , 2003, 27, 249-256.	0.1	0
320	Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. <i>Blood</i> , 2003, 101, 64-70.	0.6	253
321	Morphologic Dysplasia in De Novo Acute Myeloid Leukemia (AML) Is Related to Unfavorable Cytogenetics but Has No Independent Prognostic Relevance Under the Conditions of Intensive Induction Therapy: Results of a Multiparameter Analysis From the German AML Cooperative Group Studies. <i>Journal of Clinical Oncology</i> , 2003, 21, 256-265.	0.8	166
322	Increased Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children With Down Syndrome and Acute Myeloid Leukemia: A Report From the Children's Cancer Group Study 2891. <i>Journal of Clinical Oncology</i> , 2003, 21, 3415-3422.	0.8	158
323	Assessment of Differences in Patient Populations Selected for or Excluded From Participation in Clinical Phase III Acute Myelogenous Leukemia Trials. <i>Journal of Clinical Oncology</i> , 2003, 21, 3933-3939.	0.8	108
325	Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. <i>Blood</i> , 2003, 101, 673-680.	0.6	149
326	Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). <i>Blood</i> , 2003, 101, 2125-2131.	0.6	309
327	Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. <i>Blood</i> , 2003, 102, 1232-1240.	0.6	330
328	AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. <i>Blood</i> , 2003, 102, 2395-2402.	0.6	312
330	Classification, Treatment Goals, and Management Principles for Myelodysplastic Syndromes. <i>Cancer Control</i> , 2004, 11, 3-6.	0.7	7
331	Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2004, 22, 4384-4393.	0.8	230
332	A Novel Effective and Safe Consolidation for Patients Over 60 Years with Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2004, 10, 3965-3971.	3.2	25
333	Pilot Study of Idarubicin-Based Intensive-Timing Induction Therapy for Children With Previously Untreated Acute Myeloid Leukemia: Children's Cancer Group Study 2941. <i>Journal of Clinical Oncology</i> , 2004, 22, 150-156.	0.8	34
334	Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of MLL Gene Translocation. <i>American Journal of Clinical Pathology</i> , 2004, 122, 298-306.	0.4	49
335	Gene expression profiling of pediatric acute myelogenous leukemia. <i>Blood</i> , 2004, 104, 3679-3687.	0.6	404

#	ARTICLE	IF	CITATIONS
336	FLT3 Length Mutations as Marker for Follow-Up Studies in Acute Myeloid Leukaemia. <i>Acta Haematologica</i> , 2004, 112, 68-78.	0.7	67
337	Relevance of Pathologic Classifications and Diagnosis of Acute Myeloid Leukemia to Clinical Trials and Clinical Practice. , 2004, 121, 45-67.		15
338	Heterogeneous Patterns of FLT3 Asp835 Mutations in Relapsed de Novo Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2004, 10, 1326-1332.	3.2	50
339	Differentiation of Acute Myeloid Leukemia from B- and T-Lineage Acute Lymphoid Leukemias by Real-Time Quantitative Reverse Transcription-PCR of Lineage Marker mRNAs. <i>Clinical Chemistry</i> , 2004, 50, 1165-1173.	1.5	11
340	Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. <i>Leukemia</i> , 2004, 18, 466-475.	3.3	141
341	Translocation t(2;3)(p15â€“23;q26â€“27) in myeloid malignancies: report of 21 new cases, clinical, cytogenetic and molecular genetic features. <i>Leukemia</i> , 2004, 18, 1108-1114.	3.3	33
342	Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome. <i>Cancer Genetics and Cytogenetics</i> , 2004, 148, 29-34.	1.0	34
343	Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 2004, 155, 47-56.	1.0	39
344	Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2004, 28, 43-48.	0.4	116
345	The therapy of relapsed acute leukaemia in adults. <i>Blood Reviews</i> , 2004, 18, 39-63.	2.8	13
346	Immunophenotyping of acute leukemias and myelodysplastic syndromes. , 2004, 58A, 62-71.		77
347	Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings. <i>Cytometry</i> , 2004, 62B, 25-38.	1.8	69
348	Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. <i>Leukemia Research</i> , 2004, 28, 47-52.	0.4	24
349	Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. <i>Leukemia Research</i> , 2004, 28, 909-919.	0.4	60
350	Acute Leukemia With Natural Killer Cells Antigens in Brazilian Children. <i>Leukemia and Lymphoma</i> , 2004, 45, 739-743.	0.6	5
351	Systemic mastocytosis associated with acute myeloid leukemia: case report and implications for disease pathogenesis. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 28-33.	1.5	20
352	Unrelated cord blood transplantation for adult patients with de novo acute myeloid leukemia. <i>Blood</i> , 2004, 103, 489-491.	0.6	102
353	Randomized comparison of double induction and timed-sequential induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. <i>Blood</i> , 2004, 104, 2467-2474.	0.6	78

#	ARTICLE	IF	CITATIONS
354	Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. <i>Blood</i> , 2004, 104, 3078-3085.	0.6	249
355	Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. <i>Blood</i> , 2005, 106, 27-34.	0.6	146
356	Modern diagnostics in acute leukemias. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 56, 223-234.	2.0	70
357	FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 36, 977-983.	1.3	32
358	CEBP1± mutations in childhood acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 410-414.	3.3	45
359	Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. <i>Leukemia</i> , 2005, 19, 1416-1423.	3.3	168
360	Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. <i>Leukemia</i> , 2005, 19, 2043-2053.	3.3	80
361	Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. <i>Leukemia</i> , 2005, 19, 2063-2071.	3.3	46
362	Involvement of transforming growth factor- β 2 and thrombopoietin in the pathogenesis of myelodysplastic syndrome with myelofibrosis. <i>Leukemia</i> , 2005, 19, 1558-1566.	3.3	20
363	Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. <i>Leukemia</i> , 2005, 19, 2030-2042.	3.3	220
364	Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. <i>Leukemia</i> , 2005, 19, 2072-2081.	3.3	75
365	An unusual case of myelodysplastic syndrome with prolonged clonal stability, indolent clinical course over a decade, and spontaneous regression of AML in the terminal phase. <i>European Journal of Haematology</i> , 2005, 75, 73-77.	1.1	4
366	Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients. <i>Annals of Hematology</i> , 2005, 84, 785-791.	0.8	43
367	Leukemia and Lymphoma of Natural Killer Cells. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2005, 45, 51-70.	0.3	23
368	Treatment of childhood acute myeloid leukemia. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 917-929.	1.1	7
369	Rapid Detection of Nucleophosmin (NPM1) Mutations in Acute Myeloid Leukemia by Denaturing HPLC. <i>Clinical Chemistry</i> , 2005, 51, 2165-2167.	1.5	22
370	CD56-Positive Acute Lymphoblastic Leukemia. <i>Acta Haematologica</i> , 2005, 114, 160-163.	0.7	3
371	Quantitation of Minimal Residual Disease in Acute Myeloid Leukemia by Tryptase Monitoring Identifies a Group of Patients with a High Risk of Relapse. <i>Clinical Cancer Research</i> , 2005, 11, 6536-6543.	3.2	17

#	ARTICLE	IF	CITATIONS
372	Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2005, 46, 1007-1016.	0.6	10
373	Advances in the pathological diagnosis and biology of acute lymphoblastic leukemia. <i>Annals of Diagnostic Pathology</i> , 2005, 9, 239-257.	0.6	8
374	Immunophenotyping. , 2006, , 335-355.		3
375	Immunophenotyping. , 2006, , 150-209.		3
376	Acute myeloid leukemia. , 2006, , 499-539.		2
377	Diagnosis and classification. , 0, , 21-47.		5
378	Acute leukemia. , 2006, , 58-72.		0
379	Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. <i>British Journal of Haematology</i> , 2006, 135, 184-197.	1.2	65
380	Guidelines on the management of acute myeloid leukaemia in adults. <i>British Journal of Haematology</i> , 2006, 135, 450-474.	1.2	132
381	Improved treatment results for childhood acute myeloid leukemia in Taiwan. <i>Leukemia</i> , 2006, 20, 136-141.	3.3	37
382	AML patients with CEBP β mutations mostly retain identical mutant patterns but frequently change in allelic distribution at relapse: a comparative analysis on paired diagnosis and relapse samples. <i>Leukemia</i> , 2006, 20, 604-609.	3.3	45
383	Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial. <i>Leukemia</i> , 2006, 20, 1723-1730.	3.3	21
384	Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. <i>BMC Bioinformatics</i> , 2006, 7, 198.	1.2	26
385	Routine immunophenotyping in acute leukemia: Role in lineage assignment and reassignment. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 329-334.	0.7	13
386	Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2006, 24, 4499-4506.	0.8	173
387	Evaluation of biologic activity of tryptase secreted from blast cells in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 897-906.	0.6	11
388	Immunological Characterization and Antibacterial Function of Persisting Granulocytes in Leukemic Patients Receiving Pulse Cytosine Arabinoside-Consolidation Chemotherapy on Days 1, 3, and 5. <i>Journal of Immunology</i> , 2006, 176, 1759-1768.	0.4	5
389	Superior vena cava syndrome: Initial presentation of acute myeloid leukemia (AML-M0) with near-tetraploidy+/TdT+/CD7+/CD34+/HLA-DR+. <i>Leukemia and Lymphoma</i> , 2006, 47, 937-940.	0.6	0

#	ARTICLE	IF	CITATIONS
390	Pediatric acute myeloid leukemia: towards high-quality cure of all patients. <i>Haematologica</i> , 2007, 92, 1519-1532.	1.7	142
391	Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. <i>Blood</i> , 2007, 109, 2314-2321.	0.6	31
392	Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. <i>Blood</i> , 2007, 109, 5129-5135.	0.6	160
393	The Development of a Novel Protocol for the Treatment of De Novo Childhood Acute Myeloid Leukemia in a Single Institution in Taiwan. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 826-831.	0.3	8
394	In Vitro Cell Growth Stimulated by Recombinant Human Cytokines Can Help to Diagnose Transient Leukemia in Neonates. <i>Journal of the Formosan Medical Association</i> , 2007, 106, 365-371.	0.8	7
395	Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML. <i>Leukemia and Lymphoma</i> , 2007, 48, 2145-2151.	0.6	27
396	Estimated number of cases, regional distribution and survival of patients diagnosed with acute myeloid leukemia between 1996 and 2000 in Rio Grande do Sul, Brazil. <i>Leukemia and Lymphoma</i> , 2007, 48, 2381-2386.	0.6	16
398	The changing face of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 2283-2284.	0.6	2
399	FAB and beyond. <i>Leukemia and Lymphoma</i> , 2007, 48, 2282-2283.	0.6	1
400	Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC GIMEMA AML 13 study. <i>Haematologica</i> , 2007, 92, 389-396.	1.7	48
401	A FISH comparison of variant derivatives of the recurrent dic(17;20) of myelodysplastic syndromes and acute myeloid leukemia: Obligatory retention of genes on 17p and 20q may explain the formation of dicentric chromosomes. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 27-36.	1.5	16
402	Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2007, 49, 17-22.	0.8	71
403	Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. <i>Leukemia</i> , 2007, 21, 453-461.	3.3	74
404	The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. <i>Leukemia</i> , 2007, 21, 1177-1182.	3.3	58
405	MN1 overexpression is an important step in the development of inv(16) AML. <i>Leukemia</i> , 2007, 21, 1679-1690.	3.3	72
406	La leucémie aiguë peu différenciée (M0) aspects hématologiques, immunophénotypiques, cytogénétiques, incidence pronostique. <i>Revue Francophone Des Laboratoires</i> , 2007, 2007, 51-58.	0.0	0
407	Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. <i>British Journal of Haematology</i> , 2007, 138, 354-358.	1.2	139
408	Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria. <i>European Journal of Clinical Investigation</i> , 2007, 37, 435-453.	1.7	673

#	ARTICLE	IF	CITATIONS
409	Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group study 9004. <i>Cancer Science</i> , 2007, 98, 1350-1357.	1.7	14
410	Acute myeloid leukemia (AML-M2) with t(5;11)(q35;q13) and normal expression of cyclin D1. <i>Cancer Genetics and Cytogenetics</i> , 2007, 172, 154-157.	1.0	7
411	Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 64-69.	1.0	7
412	Cytogenetic, morphological, and immunophenotypic patterns in Omani patients with de novo acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2007, 177, 89-94.	1.0	16
413	Expression of human liver HSPGs on acute myeloid leukemia. <i>Clinical Immunology</i> , 2007, 122, 194-206.	1.4	5
414	Contrasting antigenic maturation patterns in M0-M2 versus M3 acute myeloid leukemias. <i>Experimental and Molecular Pathology</i> , 2007, 83, 269-273.	0.9	3
415	Frequent but nonrandom expression of lymphoid markers on de novo childhood acute myeloid leukemia. <i>Experimental and Molecular Pathology</i> , 2007, 83, 259-263.	0.9	9
416	Significance of age in acute myeloid leukemia patients younger than 30 years. <i>Cancer</i> , 2008, 112, 562-571.	2.0	91
417	Deletion of chromosome arm 15q in a case of minimally differentiated hypoplastic AML-M0. <i>Cancer Genetics and Cytogenetics</i> , 2008, 184, 57-61.	1.0	0
418	MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. <i>Blood</i> , 2008, 111, 1855-1861.	0.6	66
419	Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1187-1192.	3.3	168
420	Bone Marrow. , 2009, , 1536-1593.		0
421	Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10. <i>Journal of Clinical Oncology</i> , 2009, 27, 5397-5403.	0.8	180
422	Immunological detection of myeloperoxidase in poorly differentiated acute leukemia. <i>European Journal of Haematology</i> , 1993, 50, 155-159.	1.1	12
423	Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia. <i>European Journal of Haematology</i> , 1995, 55, 1-9.	1.1	21
424	Outpatient supportive therapy after induction to remission therapy in adult acute myelogenous leukaemia (AML) is feasible: a multicentre study. <i>European Journal of Haematology</i> , 1995, 54, 18-20.	1.1	28
425	Molecular cytogenetics of childhood acute myelogenous leukaemias. <i>European Journal of Haematology</i> , 1997, 59, 1-13.	1.1	22
426	A single-center population-based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender. <i>European Journal of Haematology</i> , 1999, 62, 95-102.	1.1	52

#	ARTICLE	IF	CITATIONS
427	Leukaemia cell drug resistance and prognostic factors in AML. <i>European Journal of Haematology</i> , 1999, 63, 219-224.	1.1	14
428	Determinants of urinary 8-hydroxy-2'-deoxyguanosine in Chinese children with acute leukemia. <i>Environmental Toxicology</i> , 2009, 24, 446-452.	2.1	29
429	Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. <i>Blood</i> , 2009, 114, 2220-2231.	0.6	307
430	Preferential expression of phosphatidylglucoside along neutrophil differentiation pathway. <i>Leukemia and Lymphoma</i> , 2009, 50, 1190-1197.	0.6	16
431	Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. <i>Haematologica</i> , 2009, 94, 1546-1554.	1.7	13
432	Gene expression profiling of minimally differentiated acute myeloid leukemia: M0 is a distinct entity subdivided by RUNX1 mutation status. <i>Blood</i> , 2009, 114, 3001-3007.	0.6	51
433	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	0.6	2,963
434	The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0. <i>International Journal of Hematology</i> , 2010, 91, 303-309.	0.7	20
435	Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML. <i>Cancer Genetics and Cytogenetics</i> , 2010, 202, 108-122.	1.0	27
436	Reasons for treating secondary AML as <i>de novo</i> AML. <i>European Journal of Haematology</i> , 2010, 85, 217-226.	1.1	48
437	Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome. <i>Cancer</i> , 2010, 116, 4549-4563.	2.0	99
438	Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. <i>British Journal of Haematology</i> , 2010, 149, 399-409.	1.2	52
439	Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98. <i>Journal of Clinical Oncology</i> , 2010, 28, 2682-2689.	0.8	190
441	Acute Myeloid Leukemia With Myelodysplasia-Related Changes: A New Definition. <i>Surgical Pathology Clinics</i> , 2010, 3, 1153-1164.	0.7	15
442	Expression of HOXB genes is significantly different in acute myeloid leukemia with a partial tandem duplication of MLL vs. a MLL translocation: a cross-laboratory study. <i>Cancer Genetics</i> , 2011, 204, 252-259.	0.2	12
443	Classification of Acute Leukemia. , 0, , .		7
444	Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria. <i>Pathology and Laboratory Medicine International</i> , 2011, , 17.	0.2	1
445	Immunophenotypic characterization of acute leukemia at a public oncology reference center in Maranhão, northeastern Brazil. <i>Sao Paulo Medical Journal</i> , 2011, 129, 392-401.	0.4	17

#	ARTICLE	IF	CITATIONS
446	Pediatric Acute Myeloid Leukemia. , 0, , .		0
447	Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. <i>Blood</i> , 2011, 118, 1754-1762.	0.6	52
448	CNS irradiation in pediatric acute myeloid leukemia: Equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. <i>Pediatric Blood and Cancer</i> , 2011, 57, 986-992.	0.8	25
449	Minimally differentiated acute myeloid leukemia (FAB AML-M0): Prognostic factors and treatment effects on survival—A retrospective study of 42 adult cases. <i>Leukemia Research</i> , 2011, 35, 1027-1031.	0.4	7
450	Sphingolipid Metabolism and Leukemia: A Potential for Novel Therapeutic Approaches. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2011, 11, 863-881.	0.9	9
451	Unusually Long Survival of a 67-Year-Old Patient with Near-Tetraploid Acute Myeloid Leukemia M0 without Erythroblastic and Megakaryocytic Dysplasia. <i>Acta Haematologica</i> , 2011, 126, 129-134.	0.7	5
452	Phase II Study of Intensive Post-remission Chemotherapy and Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Japan Clinical Oncology Group Study, JCOG9402. <i>Japanese Journal of Clinical Oncology</i> , 2012, 42, 394-404.	0.6	5
453	Diagnosis and classification. , 0, , 21-48.		3
454	Immunophenotyping. , 0, , 72-112.		1
455	Acute myeloid leukemia. , 0, , 395-420.		1
456	The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. <i>Haematologica</i> , 2012, 97, 21-29.	1.7	78
457	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. <i>Blood</i> , 2012, 120, 3187-3205.	0.6	451
458	Comprehensive profile of cytogenetics in 2308 Chinese children and adults with de novo acute myeloid leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2012, 49, 107-113.	0.6	15
459	Comparison of Autologous Hematopoietic Cell Transplantation and Chemotherapy as Postremission Treatment in Non-M3 Acute Myeloid Leukemia in First Complete Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 444-451.	0.2	13
460	Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial. <i>Leukemia Research</i> , 2012, 36, 1112-1118.	0.4	9
461	Historical perspectives on myelodysplastic syndromes. <i>Leukemia Research</i> , 2012, 36, 1441-1452.	0.4	17
462	Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond. <i>IUBMB Life</i> , 2012, 64, 671-675.	1.5	10
463	Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971. <i>Cancer</i> , 2012, 118, 4806-4814.	2.0	72

#	ARTICLE	IF	CITATIONS
464	Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2012, 82B, 295-304.	0.7	15
465	A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 410-417.	2.0	24
466	High incidence of acute promyelocytic leukemia specifically induced by N-nitroso-N-methylurea (NMU) in Sprague-Dawley rats. <i>Archives of Toxicology</i> , 2012, 86, 315-327.	1.9	15
467	A de novo acute myeloid leukemia (AML-M4) case with a complex karyotype and yet unreported breakpoints. <i>Molecular Cytogenetics</i> , 2013, 6, 18.	0.4	4
468	Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 41-45.	0.3	4
469	Significance of FAB subclassification of acute myeloid leukemia, NOS in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. <i>Blood</i> , 2013, 121, 2424-2431.	0.6	97
470	Diagnosis and Treatment of Childhood Acute Myeloid Leukemia. , 2013, , 355-373.		1
471	A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 114-118.	0.7	41
472	Development of a Curative Treatment within the AML-BFM Studies. <i>Klinische Padiatrie</i> , 2013, 225, S79-S86.	0.2	19
473	TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. <i>Modern Pathology</i> , 2013, 26, 195-203.	2.9	19
474	XXXVIII Congresso Nazionale AIEOP, Roma 9-11 giugno 2013 - Relazioni. <i>Mental Illness</i> , 2013, 5, 1.	0.8	0
478	Re-induction with L-DNR/FLAG Improves Response after AML Relapse, but not Long-term Survival. <i>Klinische Padiatrie</i> , 2014, 226, 323-331.	0.2	3
480	Gene Mutation Patterns in Patients with Minimally Differentiated Acute Myeloid Leukemia. <i>Neoplasia</i> , 2014, 16, 481-488.	2.3	27
481	Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis. <i>Journal of the Formosan Medical Association</i> , 2014, 113, 833-838.	0.8	13
482	Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1369-1374.	2.0	5
483	Prognostic value of the expression of phosphatase and tensin homolog and CD44 in elderly patients with refractory acute myeloid leukemia. <i>Oncology Letters</i> , 2015, 10, 103-110.	0.8	17
484	Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. <i>Annals of Hematology</i> , 2015, 94, 1327-1336.	0.8	54
485	Sex disparity in childhood and young adult acute myeloid leukemia (AML) survival: Evidence from US population data. <i>Cancer Epidemiology</i> , 2015, 39, 892-900.	0.8	27

#	ARTICLE	IF	CITATIONS
487	Acute Leukemias of Ambiguous Origin. American Journal of Clinical Pathology, 2015, 144, 361-376.	0.4	46
488	Synthesis and spectroscopic characterizations of noble metal complexes (gold, silver, platinum) in the presence of selenium, and their biological applications as antibacterial, antifungal, and anticancer. Research on Chemical Intermediates, 2015, 41, 965-1000.	1.3	7
489	Adult Acute Myeloid Leukemia – A Possible Relation to Disease Invasion and the Impact of Independent Prognostic Markers Associated with Survival Outcome. , 0, , .		0
490	Pharmacogenetic studies in pediatric acute myeloid leukemia. , 0, , 281-296.		0
491	Pediatric Leukemias and Lymphomas. , 2016, , 1455-1463.e3.		0
492	Myeloperoxidase in human peripheral blood lymphocytes: Production and subcellular localization. Cellular Immunology, 2016, 300, 18-25.	1.4	19
493	Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology. Archives of Pathology and Laboratory Medicine, 2017, 141, 1342-1393.	1.2	88
494	Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood, 2017, 129, 3314-3321.	0.6	64
495	Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004. Leukemia, 2017, 31, 2807-2814.	3.3	15
496	Myeloid Sarcoma: Presenting with Massive Cervical and Inguinal Lymphadenopathy. Head and Neck Pathology, 2017, 11, 219-223.	1.3	1
498	Clinical and prognostic significance of eosinophilia and inv(16)/t(16;16) in pediatric acute myelomonocytic leukemia (AML-M4). Pediatric Blood and Cancer, 2017, 64, e26512.	0.8	3
499	Impact of <sc>FAB</sc> classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in <sc>CR</sc> 1: An analysis of 1690 patients from the acute leukemia working party of <sc>EBMT</sc>. American Journal of Hematology, 2017, 92, 344-350.	2.0	18
500	Acute Myeloid Leukemia in a Patient With X-linked Severe Combined Immunodeficiency. Journal of Pediatric Hematology/Oncology, 2017, 39, e470-e472.	0.3	1
501	Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012. Annals of Hematology, 2017, 96, 355-362.	0.8	18
502	9 Krankhafte VerÄnderungen der Leukozyten. , 2017, , 580-672.		0
503	Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5. Cancer Gene Therapy, 2018, 25, 77-83.	2.2	7
504	Clinical challenges in <i>de novo</i> pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy, 2018, 18, 277-293.	1.1	28
505	Acute Myeloid Leukemia in Pediatric Patients: A Review About Current Diagnostic and Treatment Approaches. , 2018, , .		1

#	ARTICLE	IF	CITATIONS
506	Maintenance Therapy With Interleukinâ€”2 for Childhood AML. <i>HemaSphere</i> , 2018, 2, e159.	1.2	18
507	Increased Survival for Children With Acute Myeloid Leukemia Results From Improved Postrelapse Treatment. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 541-547.	0.3	4
508	The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know. <i>Seminars in Hematology</i> , 2019, 56, 90-95.	1.8	48
509	Associations of PGK1 promoter hypomethylation and PGK1â€”mediated PDHK1 phosphorylation with cancer stage and prognosis: a TCGA panâ€”cancer analysis. <i>Cancer Communications</i> , 2019, 39, 1-17.	3.7	23
510	The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome. <i>Cancers</i> , 2019, 11, 73.	1.7	18
511	Chronic myeloid leukemia blast crisis presented with AML of t(9;22) and t(3;14) mimicking acute lymphocytic leukemia. <i>Journal of Clinical Laboratory Analysis</i> , 2019, 33, e22961.	0.9	4
512	Feline Leukaemia Virus Associated with Leukaemia in Cats in Santa Catarina, Brazil. <i>Journal of Comparative Pathology</i> , 2019, 170, 10-21.	0.1	13
513	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. <i>Modern Pathology</i> , 2019, 32, 1373-1385.	2.9	25
514	The power and potential of integrated diagnostics in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 36-48.	1.2	44
515	Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact. <i>PLoS ONE</i> , 2020, 15, e0229593.	1.1	3
516	Differentiation of acute myeloid leukemia (AML) cells with ATRA reduces 18F-FDG uptake and increases sensitivity towards ABT-737-induced apoptosis. <i>Leukemia and Lymphoma</i> , 2021, 62, 630-639.	0.6	3
518	Cell signaling pathways as molecular targets to eliminate AML stem cells. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 160, 103277.	2.0	20
519	Outcome of acute myeloid leukaemia in Nigeria: clinicianâ€™s perspective. <i>Ecancermedicalscience</i> , 2021, 15, 1239.	0.6	2
520	Disorders of White Cells. , 0, , 398-468.		2
522	Cancer Cytogenetics. , 1999, , 345-420.		2
523	Epidemiology of Acute Childhood Leukemia. <i>Pediatric Oncology</i> , 2011, , 3-26.	0.5	3
524	Six Months of Intensive Chemotherapy for Childhood ANLL: Preliminary Results of the Study ANLL-87 of the Dutch Childhood Leukemia Study Group. <i>Hamatologie Und Bluttransfusion</i> , 1994, , 486-489.	0.0	2
525	Morphologic Basis for the MIC Classification in Acute Myeloid Leukemia. <i>Recent Results in Cancer Research</i> , 1993, 131, 339-343.	1.8	2

#	ARTICLE	IF	CITATIONS
526	Immunophenotype of Acute Myeloid Leukemia: Correlation with Morphological Characteristics and Therapy Response. Recent Results in Cancer Research, 1993, 131, 381-392.	1.8	8
527	Immunological, Ultrastructural and Molecular Features of Unclassifiable Acute Leukaemia. Recent Results in Cancer Research, 1993, 131, 41-52.	1.8	10
528	Contribution of Electron Microscopy to the Classification of Minimally Differentiated Acute Leukemias in Children. Recent Results in Cancer Research, 1993, 131, 77-87.	1.8	11
530	Acute Myeloid Leukemia. , 2011, , 672-697.		3
531	Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children. , 2009, , 331-402.		3
532	Leukocytic Disorders. , 2011, , 601-655.		4
533	Childhood Leukemia. , 2014, , 1849-1872.e11.		5
535	Detailed characterization of a complex karyotype in a patient with primary plasma cell leukaemia using multicolour spectral karyotyping and micro-FISH. The Hematology Journal, 2000, 1, 95-101.	2.0	4
536	Acute myelogenous leukaemia in older patients at St Bartholomew's Hospital: outcome with mitoxantrone and cytarabine. The Hematology Journal, 2002, 3, 237-243.	2.0	3
537	Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. British Journal of Haematology, 2000, 111, 196-203.	1.2	138
538	Minimally differentiated acute myeloid leukaemia revealed by specific cutaneous lesions. British Journal of Dermatology, 1996, 135, 119-123.	1.4	3
539	CD4dull+ hematopoietic progenitor cells in murine bone marrow. Blood, 1993, 81, 3217-3225.	0.6	28
540	The biologic properties of recombinant human thrombopoietin in the proliferation and megakaryocytic differentiation of acute myeloblastic leukemia cells. Blood, 1996, 88, 3074-3082.	0.6	33
541	CD7+ and CD56+ Myeloid/Natural Killer Cell Precursor Acute Leukemia: A Distinct Hematolymphoid Disease Entity. Blood, 1997, 90, 2417-2428.	0.6	4
544	The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood, 2000, 96, 870-877.	0.6	3
545	High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 \hat{I} B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. Blood, 2000, 96, 2862-2869.	0.6	13
546	Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood, 2000, 96, 3154-3160.	0.6	9
547	Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category. American Journal of Clinical Pathology, 2003, 119, 663-71.	0.4	15

#	ARTICLE	IF	CITATIONS
548	Acute Undifferentiated Leukemia or Minimally Differentiated Acute Myeloid Leukemia: Further Emphasis on Molecular Analysis in Leukemia Diagnosis. Juntendo Medical Journal, 2016, 62, 37-41.	0.1	2
550	O transplante de medula Ã³ssea na leucemia mielÃ³ide aguda: anÃ¡lise de 80 pacientes transplantados no complexo do Hospital das ClÃnicas da Faculdade de Medicina da Universidade de SÃ£o Paulo. Revista Brasileira De Hematologia E Hemoterapia, 2004, 26, .	0.7	2
551	Pattern of Occurrence of Leukemia at a Teaching Hospital in Eastern Region of Nepal - A Six Year Study. Journal of the Nepal Medical Association, 2013, 48, .	0.1	11
552	Ortho-topolin riboside induced differentiation through inhibition of STAT3 signaling in Acute Myeloid Leukemia HL-60 Cells. Turkish Journal of Haematology, 2019, 36, 162-168.	0.2	2
553	Acute myeloid leukemia and clonal chromosome aberrations in relation to past exposure to organic solvents. Scandinavian Journal of Work, Environment and Health, 2000, 26, 482-491.	1.7	32
554	Evaluation of Bone Marrow Specimens With Acute Myelogenous Leukemia for CD34, CD15, CD117, and Myeloperoxidase. Archives of Pathology and Laboratory Medicine, 2001, 125, 1063-1069.	1.2	20
556	Effect of allogeneic stem cell transplantation in patients with minimally differentiated acute myeloid leukemia. Journal of Hematopoietic Cell Transplantation, 2019, 8, 50-59.	0.1	1
557	The Role of the Monoclonal Antibody Anti-Myeloperoxidase (anti-MPO) in the Diagnosis and Classification of Acute Leukaemias. , 2000, , 86-92.		0
558	Acute Leukemia and Myelodysplastic Syndromes. Diagnostic Pathology, 2000, , 193-221.	0.0	0
559	Acute Lymphoblastic Leukemia in Childhood with an Unusual Immunophenotype (CD7 +/CD56 +/CD33 +). Hamatologie Und Bluttransfusion, 2001, , 78-84.	0.0	0
560	Are there Two Main Categories of de Novo Acute Myeloid Leukemias with a Normal Karyotype?. Hamatologie Und Bluttransfusion, 2001, , 54-60.	0.0	0
561	Myelodysplastisches Syndrom und akute myeloische LeukÃmie. , 2002, , 389-419.		0
563	Akute myeloische LeukÃmien. , 2003, , 312-350.		0
564	8-Yearâ€™s Experience of Ukrainian Reference Laboratory for Diagnosis of Acute Leukemias in Children. Hamatologie Und Bluttransfusion, 2003, , 12-14.	0.0	0
565	t(4;11) (q21;q23) in acute myeloid leukemia-M0 following treatment [EW92 Protocol] for Ewing's sarcoma. Revista Brasileira De Hematologia E Hemoterapia, 2004, 26, .	0.7	0
567	Acute Myeloid Leukemia. , 2004, , 179-214.		0
568	Akute lymphatische LeukÃmie (ALL). , 2006, , 2646-2690.		0
569	Akute lymphatische LeukÃmie (ALL). , 2006, , 5626-5655.		0

#	ARTICLE	IF	CITATIONS
570	Akute myeloische Leukämie (AML). , 2006, , 2605-2645.		0
571	Inmunofenotipado. , 2008, , 287-304.		0
572	Childhood Leukemia. , 2008, , 2139-2169.		1
576	Pediatric Leukemias and Lymphomas. , 2012, , 1479-1488.		0
577	Immunophenotyping. , 2012, , 353-371.		3
579	Acknowledgments / The Authors. , 2013, , 295-295.		0
582	Expression of sialosyl-Tn in colony-forming unit-erythroid, erythroblasts, B cells, and a subset of CD4+ cells. Blood, 1994, 83, 84-91.	0.6	5
583	Biological Entities in Acute Myelogenous Leukemia According to Morphological, Cytogenetic and Immunological Criteria: Data of Study AML-BFM-87. Hamatologie Und Bluttransfusion, 1996, , 524-535.	0.0	0
585	Akute myeloische Leukämie (AML, ANLL). , 1997, , 3-32.		0
586	Biological Pattern of AML-M0 Versus AML-M1: Response. Blood, 1997, 89, 345-345.	0.6	0
587	Akute myeloische Leukämie (AML). , 1999, , 1-14.		0
588	Acute Leukemia in Adults. , 1999, , 261-301.		0
589	Leukaemias. , 2014, , 597-636.		0
590	DIAGNOSIS OF ACUTE LEUKEMIA BY FLOWCYTOMETRY IN POPULATION OF TRIPURA, NORTH - EAST INDIA. Journal of Evidence Based Medicine and Healthcare, 2014, 1, 1320-1328.	0.0	0
592	Akute myeloische Leukämie (AML) im Kindesalter. , 2015, , L11.1-L11.12.		0
593	Clinico Hematological Profile of Acute Promyelocytic Leukemia. Hematology & Transfusion International Journal, 2017, 4, .	0.1	1
594	Coexistence of T-cell lymphoblastic lymphoma and acute myeloid leukemia mimicking acute lymphocytic leukemia. Indian Journal of Pathology and Microbiology, 2018, 61, 464.	0.1	1
595	Leukocyte morphology on an anti-CD antibody microarray for acute leukemia diagnosis: morphology rejuvenated. Open Access Journal of Translational Medicine & Research, 2018, 2, .	0.1	0

#	ARTICLE	IF	CITATIONS
596	Insights into Acute Myeloid Leukemia: Critical Analysis on its Wide Aspects. Abasyn Journal of Life Sciences, 2020, , 1-9.	0.2	2
597	Acute Leukemia of Myeloid, Lymphoid, and Ambiguous Lineage and Related Malignancies. Essentials of Diagnostic Pathology, 2020, , 383-533.	0.0	1
599	Myelocytic Cell Lines. , 2002, , 207-236.		0
602	Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients. American Journal of Clinical Pathology, 2004, 122, 298-306.	0.4	31
603	AML-M0: clinical entity or waste basket for immature blastic leukemias? A description of 14 patients. Annals of Hematology, 1995, 70, 297-300.	0.8	5
604	CD79 alpha expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia. American Journal of Pathology, 1996, 149, 1105-10.	1.9	30
605	Diagnosis and Classification of Acute Leukemia in Bone Marrow Trepine Biopsies, Utility of a Selected Panel of Minimal Immunohistochemical Markers. International Journal of Hematology-Oncology and Stem Cell Research, 2016, 10, 138-46.	0.3	3
606	Pediatric Acute Myeloid Leukemia—Past, Present, and Future. Journal of Clinical Medicine, 2022, 11, 504.	1.0	27
607	Early T-Cell Precursor ALL and Beyond: Immature and Ambiguous Lineage T-ALL Subsets. Cancers, 2022, 14, 1873.	1.7	8
609	Bone marrow. , 0, , 813-942.		0
611	Acute Leukaemia: Cytology, Cytochemistry and the FAB Classification. , 0, , 1-56.		1
612	Diagnosis and Classification of Acute Leukaemia. , 0, , 476-491.		2
613	Allogeneic Transplantation for Acute Myeloid Leukemia in Children. , 0, , 1040-1054.		0
614	Contribution of immunophenotypic and genotypic analyses to the diagnosis of acute leukemia. Annals of Hematology, 1995, 71, 13-27.	0.8	0
615	A Current View on Pathogenesis, Diagnosis, and Treatment of Some Rare Acute Leukemia Variants. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2022, 15, 307-326.	0.1	0
616	Circulating plasma exosomal long non-coding RNAs LINC00265, LINC00467, UCA1, and SNHG1 as biomarkers for diagnosis and treatment monitoring of acute myeloid leukemia. Frontiers in Oncology, 0, 12, .	1.3	9
618	Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells. Redox Biology, 2023, 62, 102692.	3.9	5